SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK filed a routine 6-K reporting that multiple PDMRs (including the…

GSK plc · 6-K filed Jul 14, 2026 at 11:20 ET

At the news

NEUTRALIMPACT 1/10

6-K filed Jul 14, 2026 at 11:20 ET

GSK filed a routine 6-K reporting that multiple PDMRs (including the CEO, CFO, and other senior executives) acquired ordinary shares and ADSs through the automatic reinvestment of dividends paid on July 9, 2026. The transactions are mechanical dividend reinvestments, not discretionary open-market purchases, and carry no signaling value. The filing is administrative and has no material impact on the company's financial outlook or stock price.

  • Dividend reinvestment transactions occurred on July 9, 10, and 13, 2026.
  • CEO Luke Miels acquired 20.727 ordinary shares at £19.6297 via dividend reinvestment.
  • CFO Julie Brown increased notional interest by 1,636 ordinary shares at £19.5950 via the Deferred Annual Bonus Plan.
  • President Corporate Development David Redfern acquired 5,803.725 ordinary shares at £19.6297 via dividend reinvestment.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access